Erodible coatings based on HPMC and cellulase for oral time-controlled release of drugs.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
30 Jul 2020
Historique:
received: 17 03 2020
revised: 06 05 2020
accepted: 08 05 2020
pubmed: 31 5 2020
medline: 4 3 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

Oral drug delivery systems for time-controlled release, intended for chronotherapy or colon targeting, are often in the form of coated dosage forms provided with swellable/soluble hydrophilic polymer coatings. These are responsible for programmable lag phases prior to release, due to their progressive hydration in the biological fluids. When based on high-viscosity polymers and/or manufactured by press-coating, the performance of functional hydroxypropyl methylcellulose (HPMC) layers was not fully satisfactory. Particularly, it encompassed an initial phase of slow release because of outward diffusion of the drug through a persistent gel barrier surrounding the core. To promote erosion of such a barrier, the use of a cellulolytic product (Sternzym® C13030) was here explored. For this purpose, the mass loss behavior of tableted matrices based on various HPMC grades, containing increasing percentages of Sternzym® C13030, was preliminarily studied, highlighting a clear and concentration-dependent effect of the enzyme especially with high-viscosity polymers. Subsequently, Sternzym® C13030-containing systems, wherein the cellulolytic product was either incorporated into a high-viscosity HPMC coating or formed a separate underlying layer, were manufactured. Evaluated for release, such systems gave rise to more reproducible profiles, with shortened lag phases and reduced diffusional release, as compared to the reference formulation devoid of enzyme.

Identifiants

pubmed: 32473374
pii: S0378-5173(20)30409-9
doi: 10.1016/j.ijpharm.2020.119425
pii:
doi:

Substances chimiques

Delayed-Action Preparations 0
Tablets 0
Acetaminophen 362O9ITL9D
Hypromellose Derivatives 3NXW29V3WO
Cellulase EC 3.2.1.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119425

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anastasia Foppoli (A)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Alessandra Maroni (A)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy. Electronic address: alessandra.maroni@unimi.it.

Luca Palugan (L)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Lucia Zema (L)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Saliha Moutaharrik (S)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Alice Melocchi (A)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Matteo Cerea (M)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Andrea Gazzaniga (A)

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", via G. Colombo 71, 20133 Milano, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Humans Chromatography, High Pressure Liquid Acetaminophen COVID-19 SARS-CoV-2

Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.

Prashant Kesharwani, Kratika Halwai, Saurav Kumar Jha et al.
1.00
Chitosan Humans Folic Acid Nanoparticles Drug Carriers

Classifications MeSH